Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEQ506 dose-escalation study in advanced solid tumors
NL-OMON36627Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LEQ506 in Nonhematologic neoplasms, medulloblastoma and basal cell carcinoma (BCC), sponsored by Novartis. Primary endpoint: Frequency of dose-limiting toxicities. Started Oct 2010; status: active, not recruiting.
02
Drugs
LEQ506
03
Conditions
Nonhematologic neoplasmsmedulloblastomabasal cell carcinoma (BCC)
Beyond the preview
Go deeper on NL-OMON36627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36627.